Piotr Raubo

List of Publications by Year
in descending order

12	360	1040056 9	1281871 11
papers	citations	h-index	g-index

12	12	12	687
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS^{G12C}. Journal of Medicinal Chemistry, 2022, 65, 6940-6952.	6.4	29
2	Diversity-Orientated Synthesis of Macrocyclic Heterocycles Using Double SNAr Approach.. Organic and Biomolecular Chemistry, 2021, 19, 6274-6290.	2.8	0
3	The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38Î± MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127412.	2.2	6
4	Development of oxetane modified building blocks for peptide synthesis. Organic and Biomolecular Chemistry, 2020, 18, 5400-5405.	2.8	6
5	Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles. Journal of Medicinal Chemistry, 2019, 62, 9418-9437.	6.4	25
6	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chemical Biology, 2018, 13, 3131-3141.	3.4	110
7	Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 4386-4402.	6.4	57
8	Solid-Phase Synthesis of Oxetane Modified Peptides. Organic Letters, 2017, 19, 3303-3306.	4.6	23
9	Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy. Journal of Medicinal Chemistry, 2017, 60, 3187-3197.	6.4	28
10	The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1. PLoS ONE, 2017, 12, e0189060.	2.5	37
11	Discovery of potent, selective small molecule inhibitors of Î±-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIÎ±). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3189-3193.	2.2	11
12	Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase Î±- but not Î²-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation. Chemical Communications, 2014, 50, 5388-5390.	4.1	28